Bio-Techne (TECH) Corporate presentation summary

Company overview and mission

• Headquartered in Minneapolis, MN, with approximately 3,100 employees and 34 global locations.

• FY2024 revenues reached about $1.2B, with a market cap of ~$12B.

• Mission focuses on improving quality of life by advancing science and medicine.

• 48-year leader in proteomics, serving high-growth markets with a differentiated portfolio.

Product portfolio and market segments

• Portfolio includes proteins, antibodies, proteomic analytical instruments, immunoassays, and cell & gene therapy tools.

• 72% of FY24 revenue from Protein Sciences, 28% from Diagnostics & Spatial Biology.

• Core portfolio (reagents, assays, diagnostic controls) accounts for 54% of revenue.

• End markets: 50% pharma/biotech, 21% academia, 17% diagnostics, 12% distributors.

• Geographic split: 60% Americas, 25% EMEA, 9% China, 6% APAC.

Strategic growth vectors and innovation

• Growth driven by discovery of novel biological insights, development of advanced therapeutics, and precision diagnostics.

• Innovation milestones include next-gen instruments (Leo™), multiomic spatial biology (COMET™), and GMP reagents (ProPak™).

• AI-enabled innovation and multiomic insight generation are key megatrends.

• Product portfolio supports critical applications across these growth vectors.